BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21810220)

  • 1. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma.
    Peric B; Zagar I; Novakovic S; Zgajnar J; Hocevar M
    BMC Cancer; 2011 Aug; 11():328. PubMed ID: 21810220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up.
    Aukema TS; Olmos RA; Korse CM; Kroon BB; Wouters MW; Vogel WV; Bonfrer JM; Nieweg OE
    Ann Surg Oncol; 2010 Jun; 17(6):1657-61. PubMed ID: 20151211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
    Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
    Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
    Strobel K; Bode B; Dummer R; Veit-Haibach P; Fischer DR; Imhof L; Goldinger S; Steinert HC; von Schulthess GK
    Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1774-82. PubMed ID: 19495748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma.
    Wieder HA; Tekin G; Rosenbaum-Krumme S; Klode J; Altenbernd J; Bockisch A; Nagarajah J
    Nuklearmedizin; 2013; 52(5):198-203. PubMed ID: 23969722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
    Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
    Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
    Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
    Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of [18F]-fluoro-deoxy-glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma.
    Essler M; Link A; Belloni B; Mirceva V; Souvatzoglou M; Thaler M; Haller B; Hein R; Krause BJ
    PLoS One; 2011; 6(9):e24632. PubMed ID: 21935432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
    Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
    Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?
    Schlagenhauff B; Schittek B; Ellwanger U; Stroebel W; Blum A; Schwarz M; Rassner G; Garbe C
    Melanoma Res; 2000 Oct; 10(5):451-9. PubMed ID: 11095406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients.
    Strobel K; Skalsky J; Steinert HC; Dummer R; Hany TF; Bhure U; Seifert B; Pérez Lago M; Joller-Jemelka H; Kalff V
    Dermatology; 2007; 215(3):192-201. PubMed ID: 17823514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B.
    Strobel K; Dummer R; Steinert HC; Conzett KB; Schad K; Lago MP; Soyka JD; Veit-Haibach P; Seifert B; Kalff V
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1786-95. PubMed ID: 18458901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy.
    Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E
    Br J Dermatol; 1999 Jun; 140(6):1065-71. PubMed ID: 10354072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics.
    Mruck S; Baum RP; Rinne D; Hör G
    Anticancer Res; 1999; 19(4A):2685-90. PubMed ID: 10470220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
    Weide B; Elsässer M; Büttner P; Pflugfelder A; Leiter U; Eigentler TK; Bauer J; Witte M; Meier F; Garbe C
    Br J Cancer; 2012 Jul; 107(3):422-8. PubMed ID: 22782342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
    Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
    Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
    Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
    Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomography.
    Oberholzer PA; Urosevic M; Steinert HC; Dummer R
    Dermatology; 2008; 217(4):351-5. PubMed ID: 18799883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
    Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ
    Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.